Press Releases

Date	Title	PDF Version
May 23, 2024	AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
Apr 08, 2024	Alexion data at AAN 2024 demonstrate how ULTOMIRIS® and SOLIRIS® can transform outcomes for rare neurological diseases
Apr 01, 2024	VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
Mar 25, 2024	ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
Dec 10, 2023	Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
Nov 29, 2023	AstraZeneca advances scientific leadership in hematology at ASH 2023
Sep 20, 2023	Alexion completes purchase and licence agreement for early-stage rare disease gene therapy portfolio from Pfizer
Sep 06, 2023	Update on US regulatory review of ULTOMIRIS® in NMOSD
Jul 28, 2023	Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
Jun 09, 2023	Danicopan as add-on to ULTOMIRIS® or SOLIRIS® improved hemoglobin levels and maintained disease control in patients with PNH experiencing signs or symptoms of clinically significant extravascular hemolysis

Search